Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents

Chemical Biology and Drug Design

Volumn 82, Issue 5, 2013, Pages 557-566

  Lohan, Sandeep ^a   Cameotra, Swaranjit S ^b   Bisht, Gopal S ^a  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

Antibiotic resistance; Antimicrobial peptides; Hemolytic activity; Lipopeptides

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; LIPOPEPTIDE; LIPOPEPTIDE 1; LIPOPEPTIDE 10; LIPOPEPTIDE 11; LIPOPEPTIDE 12; LIPOPEPTIDE 13; LIPOPEPTIDE 14; LIPOPEPTIDE 15; LIPOPEPTIDE 16; LIPOPEPTIDE 17; LIPOPEPTIDE 18; LIPOPEPTIDE 19; LIPOPEPTIDE 2; LIPOPEPTIDE 20; LIPOPEPTIDE 21; LIPOPEPTIDE 22; LIPOPEPTIDE 23; LIPOPEPTIDE 24; LIPOPEPTIDE 25; LIPOPEPTIDE 26; LIPOPEPTIDE 27; LIPOPEPTIDE 3; LIPOPEPTIDE 4; LIPOPEPTIDE 5; LIPOPEPTIDE 6; LIPOPEPTIDE 7; LIPOPEPTIDE 8; LIPOPEPTIDE 9; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ERYTHROCYTE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS EPIDERMIDIS;

BACILLUS SUBTILIS; ESCHERICHIA COLI; FUNGI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL PEPTIDES; HEMOLYTIC ACTIVITY; LIPOPEPTIDES;

ANTI-INFECTIVE AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL; ERYTHROCYTES; HEMOLYSIS; HUMANS; LIPOPEPTIDES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS;

EID: 84885866532     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12182     Document Type: Article

References (41)

1. Corey G.R., Stryjewski M.E., Weyenberg W., Yasothan U., Kirkpatrick P. (2009) Telavancin. Nat Rev Drug Discovery;8:929-930.
2. Yount N.Y., Bayer A.S., Xiong Y.Q., Yeaman M.R. (2006) Advances in antimicrobial peptide immunobiology. Biopolymers;84:435-458.
3. Zasloff M. (2002) Antimicrobial peptides of multicellular organisms. Nature;415:389-395.
4. Hancock R.E.W., Lehrer R. (1998) Cationic peptides: a new source of antibiotics. Trends Biotechnol;16:82-88.
5. Giuliani A., Pirri G., Nicoletto S.F. (2007) Antimicrobial peptides: an overview of a promising class of therapeutics. Cent Eur J Biol;2:1-33.
6. Brogden K.A., Ackermann M., McCray P.B., Tack B.F. (2003) Antimicrobial peptides in animals and their role in host defences. Int J Antimicrob Agents;22:465-478.
7. Balkovec J.M. (1994) Lipopeptide antifungal agents. Expert Opin Invest Drugs;3:65-82.
8. De Lucca A.J., Walsh T.J. (1999) Antifungal peptides: novel therapeutic compounds against emerging pathogens Antimicrob. Agents Chemother;43:1-11.
9. Raaijmakers J.M., De Bruijn I., De Kock M.J. (2006) Cyclic lipopeptide production by plant-associated Pseudomonas spp.: diversity, activity, biosynthesis, and regulation. Mol Plant Microbe Interact;19:699-710.
10. Jerala R. (2007) Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin Invest Drugs;16:1159-1169.
11. Straus S.K., Hancock R.E. (2006) Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta;1758:1215-1223.
12. Jung D., Rozek A., Okon M., Hancock R.E. (2004) Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol;11:949-957.
13. Epand R.M. (1997) Biophysical studies of lipopeptide-membrane interactions. Biopolymers;43:15-24.
14. Toniolo C., Crisma M., Formaggio F., Peggion C., Epand R.F., Epand R.M. (2001) Lipopeptaibols, a novel family of membrane active, antimicrobial peptides. Cell Mol Life Sci;58:1179-1188.
15. Avrahami D., Shai Y. (2003) Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D, L-amino acid-containing antimicrobial peptides: a plausible mode of action. Biochemistry;42:14946-14956.
16. Makovitzki A., Avrahami D., Shai Y. (2006) Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci USA;103:15997-16002.
17. Thevissen K., Terras F.R., Broekaert W.F. (1999) Permeabilization of fungal membranes by plant defensins inhibits fungal growth. Appl Environ Microbiol;65:5451-5458.
18. Hobden C., Teevan C., Jones L., O'Shea P. (1995) Hydrophobic properties of the cell surface of Candida albicans: a role in aggregation. Microbiology;141(Pt 8):1875-1881.
19. Ahlstrom B., Chelminska-Bertilsson M., Thompson R.A., Edebo L. (1997) Submicellar complexes may initiate the fungicidal effects of cationic amphiphilic compounds on Candida albicans. Antimicrob Agents Chemother;41:544-550.
20. Makovitzki A., Baram J., Shai Y. (2008) Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry;47:10630-10636.
21. Avrahami D., Shai Y. (2002) Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry;41:2254-2263.
22. Avrahami D., Shai Y. (2004) A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J Biol Chem;279:12277-12285.
23. Radzishevsky I.S., Rotem S., Bourdetsky D., Navon-Venezia S., Carmeli Y., Mor A. (2007) Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol;25:657-659.
24. Makovitzki A., Shai Y. (2005) pH-dependent antifungal lipopeptides and their plausible mode of action. Biochemistry;44:9775-9784.
25. Malina A., Shai Y. (2005) Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem J;390:695-702.
26. Radzishevsky I.S., Kovachi T., Porat Y., Ziserman L., Zaknoon F., Danino D., Mor A. (2008) Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem Biol;15:354-362.
27. Kamysz W., Silvestri C., Cirioni O., Giacometti A., Licci A., Della Vittoria A., Okroj M., Scalise G. (2007) In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci. Antimicrob Agents Chemother;51:354-358.
28. Barchiesi F., Giacometti A., Cirioni O., Arzeni D., Silvestri C., Kamysz W., Abbruzzetti A., Riva A., Kamysz E., Scalise G. (2007) In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. Peptides;28:1509-1513.
29. Merrifield R.B. (1986) Solid phase synthesis. Science;232:341-347.
30. Wikler M.A., Low D.E., Cockerill F.R., Sheehan D.J., Craig W.A., Tenover F.C., Dudley M.N. (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-seventh edition. CLSI (formerly NCCLS); M7-A7.
31. Svenson J., Stensen W., Brandsdal B.O., Haug B.E., Monrad J., Svendsen J.S. (2008) Antimicrobial peptides with stability toward tryptic degradation. Biochemistry;47:3777-3788.
32. Bisht G.S., Rawat D.S., Kumar A., Kumar R., Pasha S. (2007) Antimicrobial activity of rationally designed amino terminal modified peptides. Bioorg Med Chem Lett;17:4343-4346.
33. Habets M.G., Brockhurst M.A. (2012) Therapeutic antimicrobial peptides may compromise natural immunity. Biol Lett;8:416-418.
34. Jenssen H., Hamill P., Hancock R.E. (2006) Peptide antimicrobial agents. Clin Microbiol Rev;19:491-511.
35. Ahlström B., Chelminska-Bertilsson M., Thompson R.A., Edebo L. (1995) Long-chain alkanoylcholines, a new category of soft antimicrobial agents that are enzymatically degradable. Antimicrob Agents Chemother;39:50-55.
36. Shinitzky M., Haimovitz R. (1993) Chiral surfaces in micelles of enantiomeric N-palmitoyl and N-stearoylserine. J Am Chem Soc;115:12545-12549.
37. Strøm M.B., Haug B.E., Skar M.L., Stensen W., Stiberg T., Svendsen J.S. (2003) The pharmacophore of short cationic antibacterial peptides. J Med Chem;46:1567-1570.
38. Tomita M., Takase M., Bellamy W., Shimamura S. (1994) A review: the active peptide of lactoferrin. Acta Paediatr Jpn;36:585-591.
39. Rekdal Ø., Andersen J., Vorland L.H., Svendsen J.S. (1999) Construction and synthesis of lactoferricin derivatives with enhanced antibacterial activity. J Peptide Sci;5:32-45.
40. Laverty G., McLaughlin M., Shaw C., Gorman S.P., Gilmore B.F. (2010) Antimicrobial activity of short, synthetic cationic lipopeptides. Chem Biol Drug Des;75:563-569.
41. Porter E.A., Weisblum B., Gellman S.H. (2002) Mimicry of host-defense peptides by unnatural oligomers: antimicrobial β-Peptides. J Am Chem Soc;124:7324-7330.